Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | PRLHR | P49683 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500709 | 0.85 | CLPP (0.39) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6496207 | 0.85 | CLPP (0.38) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6487433 | 0.81 | KDR (0.43) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6490708 | 0.78 | TMEM97 (0.48) | PKMCLPPPTGDR2OPRD1OPRK1 | |
| SCHEMBL6487500 | 0.76 | PKM (0.41) | PKMCLPPPTGDR2OPRD1OPRK1 | |
| SCHEMBL6500706 | 0.75 | PKM (0.42) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6496700 | 0.75 | TMEM97 (0.44) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6484508 | 0.75 | CLPP (0.44) | P2RX3PKMCLPP | |
| SCHEMBL6500006 | 0.75 | PKM (0.43) | P2RX3PKMCLPPPTGDR2OPRD1 | |
| SCHEMBL6488578 | 0.74 | PKM (0.45) | P2RX3PKMCLPPPTGDR2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | P2RX3 3269/4885PKM 606/4885CLPP 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.